Daniel H LaChance

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi Associations of high-grade glioma with glioma risk alleles and histories of allergy and smoking
    Daniel H LaChance
    Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Epidemiol 174:574-81. 2011
  2. ncbi A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation
    Robert B Jenkins
    Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Nat Genet 44:1122-5. 2012
  3. ncbi Distinct germ line polymorphisms underlie glioma morphologic heterogeneity
    Robert B Jenkins
    Division of Experimental Pathology, Mayo Clinic, Rochester, MN, USA
    Cancer Genet 204:13-8. 2011
  4. ncbi Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: the Mayo Clinic experience
    Robert C Miller
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN55905, USA
    Int J Radiat Oncol Biol Phys 66:1178-86. 2006
  5. ncbi Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1
    Charles L Loprinzi
    Department of Oncology, Mayo Clinic, 200 First St, SW, Rochester, MN 55905, USA
    J Clin Oncol 29:1472-8. 2011

Collaborators

Detail Information

Publications5

  1. ncbi Associations of high-grade glioma with glioma risk alleles and histories of allergy and smoking
    Daniel H LaChance
    Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Epidemiol 174:574-81. 2011
    ..The authors' observations are consistent with a recent report that the inherited glioma risk variants in chromosome regions 9p21.3 and 20q13.3 may modify the inverse association of allergy and glioma...
  2. ncbi A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation
    Robert B Jenkins
    Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Nat Genet 44:1122-5. 2012
    ..16-6.66, P=4.7×10(-12) to 2.2×10(-8)) but not for astrocytomas with wild-type IDH1 and IDH2 (smallest P=0.26). The conserved sequence block that includes rs55705857 is consistently modeled as a microRNA...
  3. ncbi Distinct germ line polymorphisms underlie glioma morphologic heterogeneity
    Robert B Jenkins
    Division of Experimental Pathology, Mayo Clinic, Rochester, MN, USA
    Cancer Genet 204:13-8. 2011
    ..77, P = 2.6 × 10(-9)). These observations generate hypotheses concerning the possible mechanisms by which specific SNPs (or alterations in linkage disequilibrium with such SNPs) are associated with glioma development...
  4. ncbi Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: the Mayo Clinic experience
    Robert C Miller
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN55905, USA
    Int J Radiat Oncol Biol Phys 66:1178-86. 2006
    ..The aim of this study was a retrospective assessment of neurotoxicity in patients with multiple sclerosis (MS) receiving external beam radiotherapy (EBRT) to the brain...
  5. ncbi Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1
    Charles L Loprinzi
    Department of Oncology, Mayo Clinic, 200 First St, SW, Rochester, MN 55905, USA
    J Clin Oncol 29:1472-8. 2011
    ..The characteristics and natural history of the paclitaxel-acute pain syndrome (P-APS) and paclitaxel's more chronic neuropathy have not been well delineated...